Vivani Medical (VANI)
NASDAQ:VANI
Want to see VANI full AI Analyst Report?
VANI Stock Chart & Stats
$1.28
-$0.02(-1.59%)
At close: 4:00 PM EST
$1.28
-$0.02(-1.59%)
Day’s Range― - ―
52-Week Range$0.92 - $1.92
Previous CloseN/A
Volume36.09K
Average Volume (3M)216.92K
Market Cap
$112.11M
Enterprise Value$76.51M
Total Cash (Recent Filing)$19.75M
Total Debt (Recent Filing)$18.27M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 18, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding86,235,110
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-588.53
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$3.75Price Target Upside192.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advancing SLIM-1 TrialExecuting a Phase 1 semaglutide implant trial is a durable de-risking milestone: positive Phase 1 data can validate Vivani's delivery technology, create a clear regulatory pathway, and materially increase partner or investor interest ahead of a planned Phase 2 dose-ranging program in 2027.
Long-acting Implant PlatformA platform focused on sustained drug delivery addresses structural adherence and dosing gaps in chronic care. If clinically and manufacturably proven, implants can create sticky, differentiated offerings across multiple indications, providing long-term commercial leverage beyond any single drug.
Near-term Liquidity RunwayHaving ~$28M and a stated runway into mid-2027 gives the company time to advance SLIM-1 and prepare a Phase 2 pathway without immediate financing. This limited runway supports executing key clinical milestones that could materially change financing optionality over the next 6–12 months.
Bears Say
Pre-revenue OperationsOperating with no revenue means Vivani is entirely dependent on external financing and clinical success; persistent pre-revenue status amplifies dilution risk and makes the firm's long-term viability contingent on successful trials and subsequent commercial execution rather than organic cash generation.
Rising LeverageA meaningful increase in leverage reduces financial flexibility during a capital-intensive clinical stage. Higher debt relative to equity elevates refinancing and covenant risk, increases fixed obligations, and limits the company's ability to pursue opportunistic partnerships or investments without dilutive raises.
High Cash BurnSubstantial negative operating and free cash flow relative to cash on hand implies a funding gap beyond current runway. Persistent burn necessitates future capital raises that can dilute shareholders, distract management, and increase execution risk for multi-year clinical development plans.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.92 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $112.11M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.09.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 86,235,110 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.75 (192.97% Upside)
$3.75 (192.97% Upside)
Insider Transactions
Bought Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 16.3%
Last 30 Days ▼ 16.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.12%
12-Months-Change
Fundamentals
Return on Equity
-264.04%
Trailing 12-Months
Asset Growth
19.47%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
VANI Stock 12 Month Forecast
Average Price Target
$3.75
▲(192.97% Upside)
Technical Analysis
Ownership Overview
47.10% Insiders
2.29% Mutual Funds
1.23% Other Institutional Investors
47.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---